FPI-2119 Takes Center Stage at ESCMID Global 2026: Eight Posters and Two Oral Presentations Showcase Potent Bactericidal Activity Against Antibiotic-Resistant Infections
- Alia Flintoft
- Jun 3
- 4 min read
Antibiotic resistance is one of the most urgent public health challenges of our time — and the research community is fighting back. During April 2026, , Fedora Pharmaceuticals presented a comprehensive body of preclinical data on its lead candidate, FPI-2119, at ESCMID Global 2026 in Munich, Germany (April 17–21). With eight poster presentations, the breadth of evidence on display reflects the enormous potential of FPI-2119 to become a transformative new tool in the fight against Gram-negative bacterial infections.
What Is ESCMID Global 2026?
ESCMID Global is the annual congress of the European Society of Clinical Microbiology and Infectious Diseases - the world's largest infectious diseases conference, bringing together over 16,000 clinicians, researchers, and policymakers. It is the premier forum for sharing new data on diagnostics, antimicrobials, resistance mechanisms, and infection management. For Fedora, presenting at ESCMID Global 2026 is a signal to the infectious disease community that FPI-2119 is a serious candidate worthy of scientific and clinical attention.
Why FPI-2119 Matters: The AMR Crisis Context
The World Health Organization's Bacterial Priority Pathogens List (BPPL) catalogues the bacterial species posing the greatest threat to human health due to rampant resistance and dwindling treatment options. Many of the pathogens targeted by FPI-2119 - including Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, and drug-resistant Neisseria gonorrhoeae - appear on this critical list.
As Karen Bush, Ph.D., Indiana University professor emerita and Fedora Scientific Advisory Board member, explained: "Research into new antibacterial agents is scarce, yet pathogens continue to evolve new resistance mechanisms. Every year there are fewer reliably effective antibacterial agents, which puts hospital patients and the greater community at serious risk of succumbing to infections that were previously treatable."
FPI-2119 is a first-in-kind derivative of the lactivicin class - a non-β-lactam antibiotic that lacks the classical ring structure that makes β-lactam antibiotics vulnerable to the β-lactamase resistance enzymes produced by many Gram-negative bacteria. This structural distinction is critical: it means FPI-2119 is not expected to be neutralized by the same mechanisms that have eroded the effectiveness of drugs like cefepime.
The Eight ESCMID Posters: A Summary of Key Findings
Fedora's poster presentations at ESCMID Global 2026 cover a wide spectrum of preclinical data supporting the development of FPI-2119:
1. Activity Against Pseudomonas aeruginosa (Poster 2568)
Data demonstrate concentration-dependent bactericidal activity against P. aeruginosa alongside a low frequency of resistance emergence - a crucial combination for any antibiotic candidate targeting this notoriously difficult pathogen.
2. Stability Against E. coli β-Lactamase-Producing Strains (Poster 2580)
FPI-2119 maintains potent activity against Escherichia coli strains carrying a broad range of β-lactamase-encoding genes, confirming its stability in the presence of one of the most widespread resistance mechanisms in Gram-negative bacteria.
3. Enteric and Respiratory Tract Pathogens (Poster 2581)
FPI-2119 demonstrated activity against bacterial isolates including resistant strains of Campylobacter, Salmonella, Shigella, Haemophilus influenzae, and Moraxella catarrhalis - pathogens commonly associated with respiratory and intestinal tract infections.
4. Neisseria gonorrhoeae, Including Resistant Strains (Poster 2583)
All strains of N. gonorrhoeae tested were susceptible, including six strains resistant to penicillin, tetracycline, and ciprofloxacin - and three with reduced susceptibility to ceftriaxone, the current last-line recommended treatment for gonorrhea.
5. Safety Profile: No Cardiotoxicity (Poster 2599)
FPI-2119 showed no measurable cardiotoxicity and a clean off-target safety profile in preclinical testing - a highly encouraging early indicator for a drug intended for systemic use.
6. Potency Against MDR Gram-Negative Pathogens (Poster 2601)
The candidate demonstrates potency at comparable or lower concentrations than cefepime against multidrug-resistant strains of P. aeruginosa, E. coli, and K. pneumoniae - the most clinically challenging hospital-acquired pathogens.
7. Complicated UTI Mouse Model (Poster 2643)
In a murine model of complicated urinary tract infection (cUTI), FPI-2119 produced statistically significant, dose-dependent reductions in bacterial burden in both bladder and kidney - critical evidence for one of its target indications.
8. Pharmacokinetics Supporting Once-Daily Dosing (Poster 2801)
Plasma half-life and concentration data support the potential for BID (twice-daily) or QD (once-daily) dosing in humans - the latter being especially important for patient compliance and hospital formulary acceptance.
The Bigger Picture: Fedora's Pipeline Strategy
FPI-2119 is Fedora's second pipeline candidate. The company's lead candidate, nacubactam, a β-lactamase inhibitor being advanced in partnership with Meiji Seika, with Fedora holding key U.S. rights. Together, the two candidates represent a complementary approach to AMR:
Nacubactam restores bactericidal activity to existing β-lactam antibiotics by inhibiting the β-lactamases that degrade them.
FPI-2119 bypasses the β-lactamase problem entirely with a structurally distinct mechanism of action.
As Fedora CEO and founder Christopher Micetich noted: "Together, these candidates offer innovative strategies to address the urgent need to treat resistant infections."
For the complete announcement of Fedora's ESCMID 2026 presentations, including the full list of poster titles and abstract numbers, read our press release on GlobeNewswire.
Stay Connected
Follow us and join the conversation at ESCMID Global 2026:
Official ESCMID hashtag: #ESCMIDGlobal2026
AMR research tag: #AntimicrobialResistance
Antibiotic pipeline: #FPI2119 | #Antibiotics | #AMR
Follow ESCMID: linkedin.com/company/escmid
Connect with Fedora Pharmaceuticals:
Website: www.fedorapharma.com
Fedora Pharmaceuticals Inc. is an Edmonton, Alberta-based biotech founded in 2011, dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance. Learn more at www.fedorapharma.com.
Comments